The Invesco Biotechnology & Genome ETF (PBE) closed at $93.74 on August 16, 2026, recording no change from the prior session's close. The fund's flat daily performance came amid a broader pattern of gradual recovery over recent weeks.
Over the past seven days, PBE gained 1.01%, extending a trend that has pushed the fund up 2.98% over the trailing 30-day period. The incremental gains suggest measured buying interest in the biotechnology and genomics space without sharp directional momentum in either direction.
Market capitalization data for PBE was not available as of the reporting date. The ETF tracks companies involved in biotechnology and genomic research and development, a sector that can be sensitive to regulatory developments and clinical trial outcomes.
With a current price of $93.74, PBE's one-month performance reflects steady, if unspectacular, appreciation since mid-July. The fund's daily flatness on August 16 leaves its short-term trajectory intact without adding further upside on the session.
